Replies to post #250783 on Biotech Values

[Mufaso]

Jbog- Viking reported both "Discontinued treatment early" and "Discontinued study early" and clarified what each meant in the cc. As I heard it they said “Discontinued treatment early” meant the participant missed at most 2 doses but stayed in the study while "Discounted study early" meant the participant didn’t finish the study . (The exchange occurred at around the 33 min of the cc if you want to listen for yourself.) So I believe the study discontinuation numbers were the lower numbers (second row) and exceptional.

Here were the raw numbers reported in these two categories:

                         	Placebo	  VK2735  	VK2735	   VK2735	VK2735 	  VK2735 
 		                            2.5 mg	5 mg	    10 mg	15 mg	  Combined 
 	                         (n=35)	    (n=35)	(n=35)	     (n=35)	(n=35)	  (n=140) 
 Discontinued treatment early	5 (14%)	     2 (6%)	4 (11%)	     5 (14%)	7 (20%)	  18 (13%) 
 Discontinued study early	2 (6%)	     0 (0%)	1 (3%)	     2 (6%)	2 (6%)	  5 (4%) 
 

Irrespective of the discontinuations, the point is tolerability. In the VKTX cc it was stated that almost all AE’s were mild or moderate (emphasis was on mild/resolving quickly) and occurring most often in the very first week of treatment.

I believe most analysts think that a less aggressive dosing schedule would contribute to a better tolerability profile than even better than these exceptionally good numbers portray.